174 related articles for article (PubMed ID: 24900539)
1. Discovery of AM-1638: A Potent and Orally Bioavailable GPR40/FFA1 Full Agonist.
Brown SP; Dransfield PJ; Vimolratana M; Jiao X; Zhu L; Pattaropong V; Sun Y; Liu J; Luo J; Zhang J; Wong S; Zhuang R; Guo Q; Li F; Medina JC; Swaminath G; Lin DC; Houze JB
ACS Med Chem Lett; 2012 Sep; 3(9):726-30. PubMed ID: 24900539
[TBL] [Abstract][Full Text] [Related]
2. Discovery of AM-6226: A Potent and Orally Bioavailable GPR40 Full Agonist That Displays Efficacy in Nonhuman Primates.
Brown SP; Dransfield P; Vimolratana M; Zhu L; Luo J; Zhang J; Jiao X; Pattaropong V; Wong S; Zhuang R; Swaminath G; Houze JB; Lin DC
ACS Med Chem Lett; 2018 Jul; 9(7):757-760. PubMed ID: 30034614
[TBL] [Abstract][Full Text] [Related]
3. Discovery and Optimization of Potent GPR40 Full Agonists Containing Tricyclic Spirocycles.
Wang Y; Liu JJ; Dransfield PJ; Zhu L; Wang Z; Du X; Jiao X; Su Y; Li AR; Brown SP; Kasparian A; Vimolratana M; Yu M; Pattaropong V; Houze JB; Swaminath G; Tran T; Nguyen K; Guo Q; Zhang J; Zhuang R; Li F; Miao L; Bartberger MD; Correll TL; Chow D; Wong S; Luo J; Lin DC; Medina JC
ACS Med Chem Lett; 2013 Jun; 4(6):551-5. PubMed ID: 24900707
[TBL] [Abstract][Full Text] [Related]
4. AMG 837: a novel GPR40/FFA1 agonist that enhances insulin secretion and lowers glucose levels in rodents.
Lin DC; Zhang J; Zhuang R; Li F; Nguyen K; Chen M; Tran T; Lopez E; Lu JY; Li XN; Tang L; Tonn GR; Swaminath G; Reagan JD; Chen JL; Tian H; Lin YJ; Houze JB; Luo J
PLoS One; 2011; 6(11):e27270. PubMed ID: 22087278
[TBL] [Abstract][Full Text] [Related]
5. Discovery of TAK-875: A Potent, Selective, and Orally Bioavailable GPR40 Agonist.
Negoro N; Sasaki S; Mikami S; Ito M; Suzuki M; Tsujihata Y; Ito R; Harada A; Takeuchi K; Suzuki N; Miyazaki J; Santou T; Odani T; Kanzaki N; Funami M; Tanaka T; Kogame A; Matsunaga S; Yasuma T; Momose Y
ACS Med Chem Lett; 2010 Sep; 1(6):290-4. PubMed ID: 24900210
[TBL] [Abstract][Full Text] [Related]
6. Design and Synthesis of Novel, Selective GPR40 AgoPAMs.
Plummer CW; Clements MJ; Chen H; Rajagopalan M; Josien H; Hagmann WK; Miller M; Trujillo ME; Kirkland M; Kosinski D; Mane J; Pachanski M; Cheewatrakoolpong B; Nolting AF; Orr R; Christensen M; Campeau LC; Wright MJ; Bugianesi R; Souza S; Zhang X; Di Salvo J; Weinglass AB; Tschirret-Guth R; Nargund R; Howard AD; Colletti SL
ACS Med Chem Lett; 2017 Feb; 8(2):221-226. PubMed ID: 28197316
[TBL] [Abstract][Full Text] [Related]
7. Discovery of DS-1558: A Potent and Orally Bioavailable GPR40 Agonist.
Takano R; Yoshida M; Inoue M; Honda T; Nakashima R; Matsumoto K; Yano T; Ogata T; Watanabe N; Hirouchi M; Yoneyama T; Ito S; Toda N
ACS Med Chem Lett; 2015 Mar; 6(3):266-70. PubMed ID: 25815144
[TBL] [Abstract][Full Text] [Related]
8. Improving the Pharmacokinetics of GPR40/FFA1 Full Agonists.
Du X; Dransfield PJ; Lin DC; Wong S; Wang Y; Wang Z; Kohn T; Yu M; Brown SP; Vimolratana M; Zhu L; Li AR; Su Y; Jiao X; Liu JJ; Swaminath G; Tran T; Luo J; Zhuang R; Zhang J; Guo Q; Li F; Connors R; Medina JC; Houze JB
ACS Med Chem Lett; 2014 Apr; 5(4):384-9. PubMed ID: 24900845
[TBL] [Abstract][Full Text] [Related]
9. A potent class of GPR40 full agonists engages the enteroinsular axis to promote glucose control in rodents.
Luo J; Swaminath G; Brown SP; Zhang J; Guo Q; Chen M; Nguyen K; Tran T; Miao L; Dransfield PJ; Vimolratana M; Houze JB; Wong S; Toteva M; Shan B; Li F; Zhuang R; Lin DC
PLoS One; 2012; 7(10):e46300. PubMed ID: 23056280
[TBL] [Abstract][Full Text] [Related]
10. Optimization of GPR40 Agonists for Type 2 Diabetes.
Liu JJ; Wang Y; Ma Z; Schmitt M; Zhu L; Brown SP; Dransfield PJ; Sun Y; Sharma R; Guo Q; Zhuang R; Zhang J; Luo J; Tonn GR; Wong S; Swaminath G; Medina JC; Lin DC; Houze JB
ACS Med Chem Lett; 2014 May; 5(5):517-21. PubMed ID: 24900872
[TBL] [Abstract][Full Text] [Related]
11. Discovery of TUG-770: A Highly Potent Free Fatty Acid Receptor 1 (FFA1/GPR40) Agonist for Treatment of Type 2 Diabetes.
Christiansen E; Hansen SV; Urban C; Hudson BD; Wargent ET; Grundmann M; Jenkins L; Zaibi M; Stocker CJ; Ullrich S; Kostenis E; Kassack MU; Milligan G; Cawthorne MA; Ulven T
ACS Med Chem Lett; 2013 May; 4(5):441-445. PubMed ID: 23687558
[TBL] [Abstract][Full Text] [Related]
12. Discovery of Potent and Orally Bioavailable GPR40 Full Agonists Bearing Thiophen-2-ylpropanoic Acid Scaffold.
Li H; Huang Q; Chen C; Xu B; Wang HY; Long YQ
J Med Chem; 2017 Apr; 60(7):2697-2717. PubMed ID: 28277660
[TBL] [Abstract][Full Text] [Related]
13. Discovery of 3-aryl-3-ethoxypropanoic acids as orally active GPR40 agonists.
Takano R; Yoshida M; Inoue M; Honda T; Nakashima R; Matsumoto K; Yano T; Ogata T; Watanabe N; Toda N
Bioorg Med Chem Lett; 2014 Jul; 24(13):2949-53. PubMed ID: 24835985
[TBL] [Abstract][Full Text] [Related]
14. AMG 837: a potent, orally bioavailable GPR40 agonist.
Houze JB; Zhu L; Sun Y; Akerman M; Qiu W; Zhang AJ; Sharma R; Schmitt M; Wang Y; Liu J; Liu J; Medina JC; Reagan JD; Luo J; Tonn G; Zhang J; Lu JY; Chen M; Lopez E; Nguyen K; Yang L; Tang L; Tian H; Shuttleworth SJ; Lin DC
Bioorg Med Chem Lett; 2012 Jan; 22(2):1267-70. PubMed ID: 22217876
[TBL] [Abstract][Full Text] [Related]
15. SCO-267, a GPR40 Full Agonist, Improves Glycemic and Body Weight Control in Rat Models of Diabetes and Obesity.
Ueno H; Ito R; Abe SI; Ookawara M; Miyashita H; Ogino H; Miyamoto Y; Yoshihara T; Kobayashi A; Tsujihata Y; Takeuchi K; Watanabe M; Yamada Y; Maekawa T; Nishigaki N; Moritoh Y
J Pharmacol Exp Ther; 2019 Aug; 370(2):172-181. PubMed ID: 31182471
[TBL] [Abstract][Full Text] [Related]
16. Structure-Activity Study of Dihydrocinnamic Acids and Discovery of the Potent FFA1 (GPR40) Agonist TUG-469.
Christiansen E; Due-Hansen ME; Urban C; Merten N; Pfleiderer M; Karlsen KK; Rasmussen SS; Steensgaard M; Hamacher A; Schmidt J; Drewke C; Petersen RK; Kristiansen K; Ullrich S; Kostenis E; Kassack MU; Ulven T
ACS Med Chem Lett; 2010 Oct; 1(7):345-9. PubMed ID: 24900217
[TBL] [Abstract][Full Text] [Related]
17. GPR40-Mediated G
Rives ML; Rady B; Swanson N; Zhao S; Qi J; Arnoult E; Bakaj I; Mancini A; Breton B; Lee SP; Player MR; Pocai A
Mol Pharmacol; 2018 Jun; 93(6):581-591. PubMed ID: 29572336
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and biological evaluation of indane derived GPR40 agoPAMs.
Pio B; Chobanian HR; Guo Y; Josien H; Hagmann WK; Miller M; Trujillo ME; Kirkland M; Kosinski D; Mane J; Pachanski M; Cheewatrakoolpong B; Ashley E; Orr R; Wright MJ; Bugianesi R; Souza S; Zhang X; Di Salvo J; Weinglass AB; Tschirret-Guth R; Samuel K; Chen Q; Shang J; Lamca J; Ehrhart J; Nargund R; Howard AD; Colletti SL
Bioorg Med Chem Lett; 2019 Jul; 29(14):1842-1848. PubMed ID: 31109791
[TBL] [Abstract][Full Text] [Related]
19. A novel free fatty acid receptor 1 (GPR40/FFAR1) agonist, MR1704, enhances glucose-dependent insulin secretion and improves glucose homeostasis in rats.
Tsuda N; Kawaji A; Sato T; Takagi M; Higashi C; Kato Y; Ogawa K; Naba H; Ohkouchi M; Nakamura M; Hosaka Y; Sakaki J
Pharmacol Res Perspect; 2017 Aug; 5(4):. PubMed ID: 28805970
[TBL] [Abstract][Full Text] [Related]
20. Discovery of first-in-class thiazole-based dual FFA1/PPARĪ“ agonists as potential anti-diabetic agents.
Li Z; Chen Y; Zhou Z; Deng L; Xu Y; Hu L; Liu B; Zhang L
Eur J Med Chem; 2019 Feb; 164():352-365. PubMed ID: 30605833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
